Therapeutic vaccination of koalas harbouring endogenous koala retrovirus (KoRV) improves antibody responses and reduces circulating viral load.

NPJ Vaccines
Olusola OlagokePeter Timms

Abstract

The long-term survival of the koala is under serious threat from multiple factors, including infectious disease agents such as Chlamydia and koala retrovirus (KoRV). KoRV is present in both exogenous and endogenous forms, depending on the geographical location of the population. In the northern half of Australia, it is present as an endogenous infection in all koalas, making a case for an urgent need to develop a therapeutic vaccine that might prevent KoRV-associated pathologies in these koalas. To this end, we determined the therapeutic effects of vaccinating koalas harbouring endogenous KoRV with a recombinant KoRV Env protein combined with a Tri-adjuvant. We found that vaccination led to a significant increase in circulating anti-KoRV IgG levels, as well as increase in neutralising antibodies. Our study also showed that post-vaccination antibodies were able to recognize epitopes on the Env protein that were unrecognised pre-vaccination, as well as resulting in an increase in the recognition of the previously recognised epitopes. The vaccine also induced antibodies that were cross-reactive against multiple KoRV-subtypes. Finally, we found a complete clearance of KoRV-A in plasma from koalas that had detectable levels of KoRV-...Continue Reading

References

Feb 28, 2006·Journal of Virology·Nidia M OliveiraMaribeth V Eiden
Feb 1, 2011·Bioinformatics·Robert Schmieder, Robert Edwards
Sep 10, 2011·Bioinformatics·Tanja Magoč, Steven L Salzberg
Jul 27, 2012·Frontiers in Immunology·Zelda Euler, Hanneke Schuitemaker
Aug 17, 2012·Human Vaccines & Immunotherapeutics·Houda BoukhebzaGeneviève Inchauspé
Sep 26, 2012·Australian Veterinary Journal·G S SimmonsJ Meers
Feb 22, 2013·Journal of Virology·Takayuki ShojimaTakayuki Miyazawa
Jun 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Wenqin XuMaribeth V Eiden
Nov 19, 2013·FEBS Letters·Sayumi ShimodeTakayuki Miyazawa
Aug 20, 2014·Proceedings of the National Academy of Sciences of the United States of America·Bali Pulendran
Sep 28, 2014·Molecular Biology and Evolution·Yasuko IshidaAlfred L Roca
Jan 27, 2016·Human Vaccines & Immunotherapeutics·Janina E Linnik, Adrian Egli
Nov 25, 2016·Journal of Virology·K J ChappellP R Young
Jul 3, 2017·Immunogenetics·Yuanyuan ChengKatherine Belov
Jun 30, 2018·Current Opinion in HIV and AIDS·Kathryn E Stephenson
Oct 15, 2019·Cell·Tianxiong YuWilliam E Theurkauf
Mar 7, 2020·Frontiers in Immunology·Anna Rosa GarbugliaPaola Del Porto

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Datasets Mentioned

BETA
AB828004.1
KX587994.1
AHY24807.1

Methods Mentioned

BETA
affinity purification chromatography
genotyping
ELISA
PCR

Software Mentioned

BLAST
FLASH
GenePix
prinseq

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.